Rachel Haurwitz, Ph.D.

Rachel Haurwitz, Ph.D.

President and chief executive officeratCaribou Biosciences· In proxies 2022–2025

Pay in FY2025-56% from the year before · Caribou Biosciences stock 0.0% the same year

Rachel Haurwitz, Ph.D. was paid $1.8M in FY2025 (Dec), down 56%. Caribou Biosciences stock did not change that year.

Pay$100 in the stock at the end of FY21 → $11
Pay is from the Summary Compensation Table of each Caribou Biosciences proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Caribou BiosciencesPublic company · 4 yr
    • President and chief executive officer2022 – Present · 4 yrStock in role -97%
  2. Biotechnology Innovation OrganizationPublic company · 6 yr
    • Director2020 – Present · 6 yrNo stock prices for these years
  3. Seer, Inc. andPublic company · 6 yr
    • Director2020 – Present · 6 yrNo stock prices for these years
  4. Edge Animal HealthPublic company
    • Director? – PresentNo stock prices for these years
  5. Intellia Therapeutics, Inc.Public company
    • Director? – PresentNo stock prices for these years
  6. Seer, IncPublic company · 2 yr
    • Director2014 – 2016 · 2 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?